


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

*This announcement and the information herein is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein does not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein are being offered and sold outside the United States in reliance on Regulation S under the Securities Act and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

ADJUSTMENT TO CONVERSION PRICE OF
EURO750,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2025
(Stock code: 40150)

Reference is made to the announcements of Sino Biopharmaceutical Limited (the “**Company**”) dated (i) 23 January 2020 and 17 February 2020 with respect to the issue of EURO750,000,000 zero coupon convertible bonds due 2025; and (ii) 10 June 2020 with respect to, among others, the bonus issue of shares of the Company on the basis of one new Share for every two existing Shares held by the qualifying shareholders whose names appear on the register of members of the Company on Friday, 24 July 2020 (“**Bonus Issue**”). Capitalised words and expressions used herein have the same meanings as those defined in the announcement of the Company dated 23 January 2020.

In accordance with the terms and conditions of the Bonds, an adjustment will be made to the Conversion Price as a result of the Bonus Issue. The Conversion Price will be adjusted from HK\$19.09 per Share to HK\$12.72 per Share with effect from 25 July 2020.

The maximum number of Conversion Shares that will be issued upon conversion of all the outstanding Bonds at the current Conversion Price and the adjusted Conversion Price is 338,380,041 Shares and 507,836,084 Shares, respectively, representing an increase of 169,456,043 Shares (the “**Additional Conversion Shares**”) issuable under the Bonds. The Additional Conversion Shares will be issued pursuant to the General Mandate. The Company will make an application to the Stock Exchange for the listing of, and permission to deal in, the Additional Conversion Shares on the Stock Exchange.

By Order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 20 July 2020

As at the date of this announcement, the Board of the Company comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.